Monitoring severe acute maternal morbidity across Europe: A feasibility study by Chantry, A, Berrut, S, Donati, S, Gissler, M, Goldacre, R, Knight, M, Maraschini, A, Monteath, K, Morris, A, Teixeira, C, Wood, R, Zeitlin, J, Deneux-Tharaux, C

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. by Edwards, C, Mueller, G, Roelofs, A, Chantry, A, Perry, M, Russell, R, Van Camp, B, Guyon-Gellin, Y, Niesor, E, Bentzen, C, Vanderkerken, K, Croucher, P

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs by Kolovos, S, Nador, G, Kishore, B, Streetly, M, Rabin, N, Chantry, A, Yong, K, Ashcroft, J, Bowcock, S, Drayson, M, Ramasamy, K, Prieto Alhambra, D, Cooper, C, Javaid, M, Pinedo Villanueva, R

Elective vs non-elective hospital admissions by patients with multiple myeloma in England 2014 - 2018 by Ramasamy, K, Kolovos, S, Nador, G, Finley, R, Streetly, M, Kishore, B, Rabin, N, Chantry, A, Yong, K, Ashcroft, J, Bowcock, S, Drayson, M, Prieto Alhambra, D, Cooper, C, Javaid, M, Pinedo Villanueva, R

The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate) by Lawson, M, Ebetino, F, Mazur, A, Chantry, A, Paton-Hough, J, Evans, H, Lath, D, Tsoumpra, M, Lundy, M, Dobson, R, Quijano, M, Kwaasi, A, Dunford, J, Duan, X, Triffitt, J, Jeans, G, Russell, R